Acetylsalicylic acid and dipyridamole improve the early patency of aorta-coronary bypass grafts. A double-blind, placebo-controlled, randomized trial.
A total of 125 patients undergoing aorta-coronary bypass grafting for disabling angina were randomized to receive either 330 mg of acetylsalicylic acid (aspirin) plus 75 mg of dipyridamole three times daily or a placebo for 6 months postoperatively. In addition, all patients were given warfarin for 3 months. Repeat angiography was performed at 6 months in 103 patients. In the treatment group 95 grafts were implanted in 48 patients, of which 87 were patent (91.6% patency rate). This figure compares with 88 grafts patent out of 118 implanted in 55 patients in the placebo group (74.6% patency rate) (p less than 0.01). We conclude that antiplatelet therapy improves the early patency of saphenous vein aorta-coronary bypass grafts.
D000328:Adult; D001241:Aspirin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D001026:Coronary Artery Bypass; D004176:Dipyridamole / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006083:Graft Occlusion, Vascular / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010919:Placebos; D011897:Random Allocation
D010919:Placebos; D004176:Dipyridamole; D001241:Aspirin